Product Name:2-Fluoro-4-iodoaniline

IUPAC Name:2-fluoro-4-iodoaniline

CAS:29632-74-4
Molecular Formula:C6H5FIN
Purity:95%+
Catalog Number:CM118182
Molecular Weight:237.02

Packing Unit Available Stock Price($) Quantity
CM118182-500g in stock ǸǸƚ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:29632-74-4
Molecular Formula:C6H5FIN
Melting Point:-
Smiles Code:NC1=CC=C(I)C=C1F
Density:
Catalog Number:CM118182
Molecular Weight:237.02
Boiling Point:261.7°C at 760 mmHg
MDL No:MFCD00011738
Storage:Keep in dark place, store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Mirdametinib
SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.

Related Products